Our understanding of Alzheimer's disease (AD) pathophysiology remains incomplete. Here
we used quantitative mass spectrometry and coexpression network analysis to conduct the …

Alzheimer's disease (AD) pathology develops many years before the onset of cognitive
symptoms. Two pathological processes—aggregation of the amyloid-β (Aβ) peptide into …

Alzheimer's disease is a pervasive neurodegenerative disorder, the molecular complexity of
which remains poorly understood. Here, we analysed 80,660 single-nucleus transcriptomes …

The biological processes that are disrupted in the Alzheimer's disease (AD) brain remain
incompletely understood. In this study, we analyzed the proteomes of more than 1,000 brain …

Background The complicated cellular and biochemical changes that occur in brain during
Alzheimer's disease are poorly understood. In a previous study we used an unbiased label …

Alzheimer's disease (AD) lacks protein biomarkers reflective of its diverse underlying
pathophysiology, hindering diagnostic and therapeutic advancements. Here, we used …

Alzheimer's disease (AD) is a neurodegenerative disease with heterogenous
pathophysiological changes that develop years before the onset of clinical symptoms. These …

The repeated failures of amyloid-targeting therapies have challenged our narrow
understanding of Alzheimer's disease (AD) pathogenesis and inspired wide-ranging …

Proteomic studies of human Alzheimer's disease brain tissue have potential to identify
protein changes that drive disease, and to identify new drug targets. Here, we analyse 38 …

The incidence of Alzheimer's disease (AD), the leading cause of dementia, increases rapidly
with age, but why age constitutes the main risk factor is still poorly understood. Brain ageing …